Amylyx Pharmaceuticals' (AMLX) Relyvrio Receives Approval from FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Amylyx Pharmaceuticals (AMLX) Sets List Price of $12,500 for 28-Day Supply of ALS Drug Relyvrio -- WSJ
September 30, 2022 8:49 AM EDTAmylyx Pharmaceuticals (NASDAQ: AMLX) Sets List Price of $12,500 for 28-Day Supply of ALS Drug Relyvrio -- WSJ
... MoreAmylyx Pharmaceuticals (AMLX) Confirms FDA Approval of RELYVRIO for the Treatment of ALS
September 30, 2022 7:05 AM EDTAmylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for the treatment of adults with amyotrophic lateral sclerosis (ALS). RELYVRIO (previously known as AMX0035 in the U.S.) significantly slowed the loss of physical function in people living with ALS in a randomized, placebo-controlled clinical trial. RELYVRIO can be taken as a monotherapy or with existing approved treatments.
Todays FDA approval of RELYVRIO is an exciting milestone for the ALS community and is a major step... More
